Pierluigi Toniutto

Prof. Pierluigi Toniutto

Hepatology and Liver Transplantation Unit, Department of Specialized Medicine Azienda Sanitaria Universitaria Integrata, Academic Hospital, Udine, Italy
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Lancet
Verified
Journal Article
Closed access
PCPaolo Caraceni
Paolo Caraceni
OROliviero Riggio
Oliviero Riggio
PAPaolo Angeli
Paolo Angeli
CACarlo Alessandria
Carlo Alessandria
SNSergio Neri
Sergio Neri
FSFrancesco Salerno
Francesco Salerno

18 July 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
XLXiangdong Liu
Xiangdong Liu
PIPietro Invernizzi
Pietro Invernizzi
YLYue Lu
Yue Lu
RKRoman Kosoy
Roman Kosoy
YLYan Lu
Yan Lu
MSMichael F Seldin
Michael F Seldin

16 January 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
MCMarta Cavallin
Marta Cavallin
PKPatrick S. Kamath
Patrick S. Kamath
Manuela MerliManuela Merli
Manuela Merli
SFSilvano Fasolato
Silvano Fasolato
PTPierluigi Toniutto
Pierluigi Toniutto
FSfor the Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome
for the Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome
Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment. Terlipressin with albumin is effective in the reversal of HRS. Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatment of HRS. The aim was to compare the effectiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of HRS in a randomized controlled trial. Twenty‐seven patients were randomized to receive terlipressin with albumin (TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group). The TERLI group received terlipressin by intravenous infusion, initially 3 mg/24 hours, progressively increased to 12 mg/24 hours if there was no response. The MID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice daily, with the dose increased to a maximum of 12.5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 μg thrice daily and up to 200 μg thrice daily. Both groups received albumin intravenously 1 g/kg of body weight on day 1 and 20‐40 g/day thereafter. There was a significantly higher rate of recovery of renal function in the TERLI group (19/27, 70.4%) compared to the MID/OCT group (6/21, 28.6%), P = 0.01. Improvement in renal function and lower baseline Model for End‐Stage Liver Disease score were associated with better survival. Conclusion: Terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal function in patients with HRS (Hepatology 2015;62:567–574

1 October 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
ETEric Trépo
Eric Trépo
PNPierre Nahon
Pierre Nahon
Gianluca BontempiGianluca Bontempi
Gianluca Bontempi
LVLuca Valenti
Luca Valenti
EFEdmondo Falleti
Edmondo Falleti
PDPierre Deltenre
Pierre Deltenre
The incidence of hepatocellular carcinoma (HCC) is increasing in Western countries. Although several clinical factors have been identified, many individuals never develop HCC, suggesting a genetic susceptibility. However, to date, only a few single-nucleotide polymorphisms have been reproducibly shown to be linked to HCC onset. A variant (rs738409 C>G, encoding for p.I148M) in the PNPLA3 gene is associated with liver damage in chronic liver diseases. Interestingly, several studies have reported that the minor rs738409[G] allele is more represented in HCC cases in chronic hepatitis C (CHC) and alcoholic liver disease (ALD). However, a significant association with HCC related to CHC has not been consistently observed, and the strength of the association between rs738409 and HCC remains unclear. We performed a meta-analysis of individual participant data including 2,503 European patients with cirrhosis to assess the association between rs738409 and HCC, particularly in ALD and CHC. We found that rs738409 was strongly associated with overall HCC (odds ratio [OR] per G allele, additive model = 1.77; 95% confidence interval [CI]: 1.42-2.19; P = 2.78 × 10−7). This association was more pronounced in ALD (OR = 2.20; 95% CI: 1.80-2.67; P = 4.71 × 10−15) than in CHC patients (OR = 1.55; 95% CI: 1.03-2.34; P = 3.52 × 10−2). After adjustment for age, sex, and body mass index, the variant remained strongly associated with HCC. Conclusion: Overall, these results suggest that rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent and provide a strong argument for performing further mechanistic studies to better understand the role of PNPLA3 in HCC development. (Hepatology 2014;59:2170–2177)

14 August 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
Umberto CilloUmberto Cillo
Umberto Cillo
PBPatrizia Burra
Patrizia Burra
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
LBL. Belli
L. Belli
APA. D. Pinna
A. D. Pinna
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
Since Italian liver allocation policy was last revised (in 2012), relevant critical issues and conceptual advances have emerged, calling for significant improvements. We report the results of a national consensus conference process, promoted by the Italian College of Liver Transplant Surgeons (for the Italian Society for Organ Transplantation) and the Italian Association for the Study of the Liver, to review the best indicators for orienting organ allocation policies based on principles of urgency, utility, and transplant benefit in the light of current scientific evidence. MELD exceptions and hepatocellular carcinoma were analyzed to construct a transplantation priority algorithm, given the inequity of a purely MELD‐based system for governing organ allocation. Working groups of transplant surgeons and hepatologists prepared a list of statements for each topic, scoring their quality of evidence and strength of recommendation using the Centers for Disease Control grading system. A jury of Italian transplant surgeons, hepatologists, intensivists, infectious disease specialists, epidemiologists, representatives of patients’ associations and organ‐sharing organizations, transplant coordinators, and ethicists voted on and validated the proposed statements. After carefully reviewing the statements, a critical proposal for revising Italy's current liver allocation policy was prepared jointly by transplant surgeons and hepatologists.

1 September 2013 in Digestive and Liver Disease
Verified
Journal Article
Open access
LBLuigi Bolondi
Luigi Bolondi
Umberto CilloUmberto Cillo
Umberto Cillo
MCMassimo Colombo
Massimo Colombo
ACAntonio Craxì
Antonio Craxì
FFFabio Farinati
Fabio Farinati
PTPierluigi Toniutto
Pierluigi Toniutto
Patients with hepatocellular carcinoma should be managed with a multidisciplinary approach framed in a network where all the diagnostic techniques and therapeutic resources are available in order to provide the optimal level of care. Given this assumption, the Coordinating Committee of the Italian Association for the Study of the Liver nominated a panel of experts to elaborate practical recommendations for the multidisciplinary management of hepatocellular carcinoma aiming to provide: (1) homogeneous and efficacious diagnostic and staging work-up, and (2) the best treatment choice tailored to patient status and tumour stage at diagnosis. The 2010 updated American Association for the Study of Liver Disease Guidelines for hepatocellular carcinoma were selected as the reference document. For each management issue, the American Association for the Study of Liver Disease recommendations were briefly summarised and discussed, according to both the scientific evidence published after their release and the clinical expertise of the Italian centres taking care of these patients. The Italian Association for the Study of the Liver expert panel recommendations are finally reported.